JP6385938B2 - 外用ステロイド組成物および方法 - Google Patents

外用ステロイド組成物および方法 Download PDF

Info

Publication number
JP6385938B2
JP6385938B2 JP2015537793A JP2015537793A JP6385938B2 JP 6385938 B2 JP6385938 B2 JP 6385938B2 JP 2015537793 A JP2015537793 A JP 2015537793A JP 2015537793 A JP2015537793 A JP 2015537793A JP 6385938 B2 JP6385938 B2 JP 6385938B2
Authority
JP
Japan
Prior art keywords
halobetasol
lotion
composition
external
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015537793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534980A (ja
JP2015534980A5 (cg-RX-API-DMAC7.html
Inventor
エー. ジョンソン,キース
エー. ジョンソン,キース
エフ. ポップ,カール
エフ. ポップ,カール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mical Pharmaceuticals H Series LLC
Original Assignee
Mical Pharmaceuticals H Series LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50485547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6385938(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mical Pharmaceuticals H Series LLC filed Critical Mical Pharmaceuticals H Series LLC
Publication of JP2015534980A publication Critical patent/JP2015534980A/ja
Publication of JP2015534980A5 publication Critical patent/JP2015534980A5/ja
Application granted granted Critical
Publication of JP6385938B2 publication Critical patent/JP6385938B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015537793A 2012-10-18 2013-10-16 外用ステロイド組成物および方法 Expired - Fee Related JP6385938B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261715467P 2012-10-18 2012-10-18
US61/715,467 2012-10-18
US13/921,833 2013-06-19
US13/921,859 2013-06-19
US13/921,859 US20140112959A1 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
US13/921,833 US8962028B2 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
PCT/US2013/065266 WO2014062817A1 (en) 2012-10-18 2013-10-16 Topical steroid composition and method

Publications (3)

Publication Number Publication Date
JP2015534980A JP2015534980A (ja) 2015-12-07
JP2015534980A5 JP2015534980A5 (cg-RX-API-DMAC7.html) 2016-11-17
JP6385938B2 true JP6385938B2 (ja) 2018-09-05

Family

ID=50485547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537793A Expired - Fee Related JP6385938B2 (ja) 2012-10-18 2013-10-16 外用ステロイド組成物および方法

Country Status (19)

Country Link
US (3) US8962028B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919753A1 (cg-RX-API-DMAC7.html)
JP (1) JP6385938B2 (cg-RX-API-DMAC7.html)
KR (1) KR101832041B1 (cg-RX-API-DMAC7.html)
CN (1) CN104884043B (cg-RX-API-DMAC7.html)
AP (1) AP2015008420A0 (cg-RX-API-DMAC7.html)
AU (1) AU2013331271B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008951A2 (cg-RX-API-DMAC7.html)
CA (1) CA2888853C (cg-RX-API-DMAC7.html)
EA (1) EA029494B1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN04160A (cg-RX-API-DMAC7.html)
MX (1) MX371362B (cg-RX-API-DMAC7.html)
MY (1) MY179354A (cg-RX-API-DMAC7.html)
NZ (1) NZ706918A (cg-RX-API-DMAC7.html)
PH (1) PH12015500859B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201502931YA (cg-RX-API-DMAC7.html)
UA (1) UA115073C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014062817A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201502692B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
HUE050603T2 (hu) 2015-06-18 2020-12-28 Bausch Health Ireland Ltd Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534382B2 (en) 2017-06-19 2022-12-27 Novan, Inc. Topical compositions and methods of using the same
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
WO2020181395A1 (en) 2019-03-14 2020-09-17 Crescita Therapeutics Inc. Rinse-off compositions and uses thereof for delivery of active agents
CN109833291B (zh) * 2019-04-03 2022-08-26 普霖贝利生物医药研发(上海)有限公司 一种稳定的丙酸氯倍他索软膏及其制备方法
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
IL319352A (en) 2022-09-15 2025-05-01 Arcutis Biotherapeutics Inc Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug
AU2023352919A1 (en) 2022-09-29 2025-03-13 Adora Life Science, Inc. Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
DE3225848A1 (de) * 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
TW218849B (cg-RX-API-DMAC7.html) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
CA2143515A1 (en) 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
US6647058B1 (en) 1997-06-23 2003-11-11 Paradyne Corporation Performance customization system and process for optimizing XDSL performance
US6171985B1 (en) 1997-12-01 2001-01-09 3M Innovative Properties Company Low trauma adhesive article
US6673374B2 (en) 1998-07-31 2004-01-06 Howard Murad Pharmaceutical compositions and methods for managing skin conditions
US6315980B1 (en) 1998-09-25 2001-11-13 Shiseido Company, Ltd. Skin barrier function recovery and promotion composition and evaluation method thereof
AU1803100A (en) * 1999-01-06 2000-07-24 Taisho Pharmaceutical Co., Ltd. Amelometasone lotion
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6790203B2 (en) 2000-12-20 2004-09-14 Sca Hygiene Products Ab Absorbent product comprising leakage barriers
US6830758B2 (en) 2001-04-02 2004-12-14 Lectec Corporation Psoriasis patch
US6781027B2 (en) 2001-12-14 2004-08-24 Kimberly-Clark Worldwide, Inc. Mixed denier fluid management layers
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7208485B2 (en) 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US20050153946A1 (en) * 2003-12-24 2005-07-14 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
AU2005213895A1 (en) 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070189980A1 (en) 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US20070196457A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US20070167420A1 (en) * 2005-04-07 2007-07-19 Daniella Gutman Process for preparing a crystalline form of halobetasol propionate
RU2009141539A (ru) 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) Комплекс фармацевтического наполнителя
MX2010002592A (es) * 2007-09-10 2010-03-30 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica para la combinacion de acido fusidico y corticoesteroides.
CH701253A1 (de) 2009-06-12 2010-12-15 Mibelle Ag Verwendung eines Extraktes aus Schneealgen in kosmetischen oder dermatologischen Formulierungen.
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration

Also Published As

Publication number Publication date
US20140112959A1 (en) 2014-04-24
MY179354A (en) 2020-11-04
ZA201502692B (en) 2016-01-27
CN104884043B (zh) 2018-12-11
BR112015008951A2 (pt) 2017-07-04
CA2888853C (en) 2019-02-12
JP2015534980A (ja) 2015-12-07
KR101832041B1 (ko) 2018-02-23
WO2014062817A1 (en) 2014-04-24
CA2888853A1 (en) 2014-04-24
MX371362B (es) 2020-01-27
US20140112991A1 (en) 2014-04-24
EA201590730A1 (ru) 2015-08-31
PH12015500859A1 (en) 2015-06-22
SG11201502931YA (en) 2015-05-28
NZ706918A (en) 2019-01-25
EP2919753A1 (en) 2015-09-23
HK1214154A1 (zh) 2016-07-22
AU2013331271A1 (en) 2015-05-07
AP2015008420A0 (en) 2015-05-31
PH12015500859B1 (en) 2015-06-22
CN104884043A (zh) 2015-09-02
US20150119827A1 (en) 2015-04-30
KR20150069005A (ko) 2015-06-22
UA115073C2 (uk) 2017-09-11
US8962028B2 (en) 2015-02-24
EA029494B1 (ru) 2018-04-30
MX2015004863A (es) 2016-02-05
IN2015DN04160A (cg-RX-API-DMAC7.html) 2015-10-16
AU2013331271B2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
JP2015534980A (ja) 外用ステロイド組成物および方法
ES2914112T3 (es) Composiciones farmacéuticas tópicas
Tamarkin Foam: a unique delivery vehicle for topically applied formulations
JP2021527037A (ja) ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
US9795564B2 (en) Oil-based foamable carriers and formulations
JP5548275B2 (ja) ビタミンd類似体および共溶媒−界面活性剤混合物から成る医薬品組成物
JP2023502539A (ja) 高クラフト温度アニオン性界面活性剤を使用した皮膚症状の処置
EP2515866B1 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US20160213690A1 (en) Compositions and methods for the treatment of skin diseases
US12011437B1 (en) Roflumilast formulations with an improved pharmacokinetic profile
KR20210039407A (ko) 국소 조성물
CN108472254A (zh) 环孢霉素a局部组合物
US9254296B2 (en) Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
CN115397398A (zh) 环状酯肽的局部药物制剂
ES2760520T3 (es) Composición de emulsión antipsoriásica que se compone de cefazolina
HK1214154B (en) Topical Steroid Composition And Method
HK1177695B (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150604

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180808

R150 Certificate of patent or registration of utility model

Ref document number: 6385938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees